End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al.

Christopher Melani,Wyndham H Wilson,Mark Roschewski

doi:10.3324/haematol.2018.199547

End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al.

Christopher Melani, Wyndham H Wilson + Show 1 more

Open Access

https://doi.org/10.3324/haematol.2018.199547

Copy DOI

Journal: Haematologica	Publication Date: Jul 31, 2018
Citations: 1	License type: cc-by-nc

Affiliation: National Cancer Institute, National Institutes of Health, Center for Cancer Research

#Dose-adjusted EPOCH-R #Primary Mediastinal B-cell Lymphoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

We recently published additional and extended followup results from our prospective phase 2 study and independent series of DA-EPOCH-R in the front-line treatment of primary mediastinal B-cell lymphoma (PMBCL).[1][1] In this study, analyses of singular and serial end-of-treatment (EOT) FDG-PET

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Haematologica

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.